In a male endurance cyclist on long‑term testosterone therapy with MRI showing late gadolinium enhancement increasing from 4 % to 12 %, could this LGE be present due solely to isolated left‑ventricular hypertrophy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

No—LGE at 12% Cannot Be Attributed to LVH Alone and Demands Urgent Investigation for Underlying Cardiomyopathy

An increase in late gadolinium enhancement from 4% to 12% in an endurance cyclist with LVH is pathological and cannot be explained by physiological hypertrophy alone. This degree and progression of LGE signals myocardial replacement fibrosis requiring immediate evaluation for underlying cardiomyopathy, particularly given the context of long-term testosterone therapy.

Why LGE is NOT Present in Isolated Physiological LVH

The European Association of Preventive Cardiology/European Association of Cardiovascular Imaging guidelines explicitly state that LGE is used to distinguish adaptive athletic changes from disease 1. While the guidelines acknowledge that "small spots of fibrosis have been occasionally reported in endurance athletes without other obvious disease," they emphasize that:

  • LGE helps distinguish potentially adaptive changes from diseases in the context of diffuse LV hypertrophy 1
  • The presence of LGE is a key differentiating feature between athlete's heart and pathological conditions like HCM 1
  • In the diagnostic algorithm for athlete's heart versus HCM, positive LGE on CMR points toward HCM, not physiological adaptation 1

The Significance of 12% LGE

The 2024 AHA/ACC HCM guidelines establish that extensive LGE ≥15% of LV mass represents a significant (2-fold) increase in sudden cardiac death risk 2. Your patient at 12% is approaching this critical threshold, and the tripling of LGE from 4% to 12% represents concerning disease progression.

Recent research confirms that:

  • In competitive amateur cyclists, LGE occurred in only 33% of males, and when present was predominantly at the RV insertion point (79%) 3
  • Non-RVIP LGE in cyclists was associated with adverse remodeling, reduced RV ejection fraction, and elevated troponin—suggesting a distinct pathological phenotype 3
  • The location and extent of LGE matter critically for prognosis

Critical Differential Diagnoses to Exclude

1. Hypertrophic Cardiomyopathy (Most Likely)

The 2020 AHA/ACC HCM guideline notes that CMR with LGE has excellent ability to outline myocardial replacement fibrosis and is commonly used for differentiation between diseased and adaptive athletes 4. In HCM:

  • LGE is typically patchy or confluent
  • Can occur in various patterns (mid-wall, subepicardial)
  • Extensive LGE is associated with increased risk for life-threatening ventricular arrhythmias 2

2. Infiltrative/Storage Diseases

Given the testosterone therapy context, consider:

  • Fabry disease: Shows specific mid-wall inferolateral LGE patterns 5, 6
  • Amyloidosis: Diffuse subendocardial LGE 1
  • Anderson-Fabry disease: Subepicardial basal LGE 1

3. Inflammatory Cardiomyopathy

Mid-wall and subepicardial LGE patterns suggest inflammatory disease-related necrosis or scars (myocarditis, sarcoidosis) 1

4. Arrhythmogenic Cardiomyopathy

Particularly left-dominant variant, which shows fibro-fatty replacement in sub-epicardial or mid-wall regions 7

Testosterone Therapy as a Confounding Factor

The FDA label for testosterone indicates it is approved only for replacement therapy in conditions of testosterone deficiency 8. Long-term use in a male endurance athlete raises concerns about:

  • Supraphysiologic dosing potentially contributing to pathological cardiac remodeling
  • Increased risk of cardiovascular events
  • Possible contribution to myocardial fibrosis development

The testosterone label warns about cardiac risks but does not specifically address LGE development 8.

Immediate Clinical Actions Required

Comprehensive Cardiac Evaluation:

  1. Detailed family history for sudden cardiac death, HCM, or inherited cardiomyopathies

  2. 12-lead ECG looking for major abnormalities (ST-segment/T-wave inversions, pathological Q waves)

  3. Echocardiography with strain imaging to assess:

    • LV cavity size (should be >54mm in athlete's heart) 1
    • Segmental vs. diffuse hypertrophy pattern
    • LVOT obstruction
    • Diastolic function (septal e' velocity, E/A ratio)
    • Global longitudinal strain (<-15% suggests pathology) 1
  4. 24-hour Holter monitoring and exercise testing to detect ventricular arrhythmias

  5. Genetic testing for sarcomeric mutations (HCM), desmosomal genes (AC), and storage diseases

  6. Cardiopulmonary exercise testing to assess functional capacity

  7. Review testosterone dosing and consider cessation to assess for reversibility

Pattern Analysis of LGE:

The location and distribution of the 12% LGE is critical:

  • RV insertion point only: May represent physiological stress (though 12% is still excessive) 3
  • Mid-wall inferolateral: Suggests Fabry disease 5, 6
  • Patchy/confluent: Suggests HCM 1, 4
  • Subendocardial: Consider infiltrative disease 1

Risk Stratification:

The progression from 4% to 12% LGE indicates active disease progression requiring:

  • Assessment for ICD candidacy if HCM confirmed 2
  • Evaluation for heart failure risk
  • Consideration of sports restriction pending diagnosis 7, 1

Common Pitfalls to Avoid

  1. Attributing significant LGE to "athlete's heart": This is a dangerous assumption that delays diagnosis of treatable cardiomyopathies
  2. Ignoring the progression: The tripling of LGE extent is never physiological
  3. Failing to assess LGE pattern: Location matters for differential diagnosis
  4. Overlooking testosterone as a contributor: Supraphysiologic androgen use may contribute to pathological remodeling
  5. Delaying genetic testing: Many causes of LGE with LVH are inherited and have treatment implications

Bottom line: 12% LGE with documented progression cannot be dismissed as physiological LVH and requires comprehensive evaluation for underlying cardiomyopathy with potential implications for sudden cardiac death risk, treatment, and sports participation.

References

Related Questions

In a male endurance cyclist on long‑term testosterone therapy with left‑ventricular hypertrophy and increasing late gadolinium enhancement (4%→12%) on cardiac MRI, how do recreational versus competitive cycling differ, and which intensity/volume is acceptable versus unacceptable?
How should I manage a patient with hypertrophic cardiomyopathy who has experienced a rapid increase in late gadolinium enhancement from 4% to 12% over one year, new systolic anterior motion (SAM) of the mitral valve, new right‑ventricular wall thickening, and a newly detected supraventricular tachyarrhythmia on Holter monitoring?
Should a cardiac magnetic resonance imaging (MRI) be ordered for septal hypertrophy identified on echocardiography?
Which of the following are appropriate components of therapeutic management for systemic vasculitis with renal involvement: maintenance therapy with angiotensin-converting enzyme (ACE) inhibitors, induction therapy with high-dose corticosteroids alone, administration of cyclophosphamide or rituximab during the acute phase, administration of azathioprine during the acute phase, or induction therapy with corticosteroids and immunosuppressants?
How should I manage a patient with a 2‑year history of intense nasal pruritus, constant bright‑white rhinorrhea with occasional small hard black particles, increased salivation, onset after pneumonia hospitalization, and comorbid diabetes and hypertension treated with metformin, aspirin, and losartan?
In a prisoner presenting with fever, productive foul‑smelling green sputum, weight loss, cachexia, dyspnea, and a chest radiograph demonstrating a thick‑walled, irregular mass with an air‑fluid level in the left lower lobe, what is the most appropriate next step in management?
In a 42-year-old female with urinary‑tract infection symptoms and a positive rapid plasma reagin (RPR) and treponemal antibody test, what antibiotics should be initiated when penicillin is unavailable due to a national shortage?
What is the lowest commercially available dose of olanzapine for adult patients?
What is the appropriate evaluation and management for a 53-year-old female presenting with hot flashes and night sweats?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.